John D. Shaughnessy

High Impact

Professor

UAMS primary UA Little Rock

Also affiliated: University of Maryland, Baltimore (2003); National Institutes of Health (1993); Arkansas Children's Hospital (1998); Langley Research Center (1973–1992); Hackensack University Medical Center (2003); Mayo Clinic (2005–2009); Memorial Sloan Kettering Cancer Center (2003); Harvard University (2003–2013); Central South University (2023); Inserm (2002–2003); Duke University (2009); University of Basel (2005); BP (United Kingdom) (2007); Medical College of Wisconsin (2003); Cornell University (2001); University of Utah (2009); University of Arkansas Medical Center (1999–2024); Aarhus University Hospital (2002); Yale University (2009); Universitätsklinikum Erlangen (2003); Fred Hutch Cancer Center (2000–2002); Centre Hospitalier Universitaire de Montpellier (2003); Cancer Research And Biostatistics (2003–2012); Hôpital Gui de Chauliac (2002); Dana-Farber Cancer Institute (2013); Signal Genetics (United States) (2012–2016); National Aeronautics and Space Administration (1984); Mayo Clinic in Arizona (2005–2009); Duke Medical Center (2009); Frederick National Laboratory for Cancer Research (1995–1997); Hôpital Lapeyronie (2002); Dana-Farber/Harvard Cancer Center (2003–2013); The Institute of Statistical Mathematics (2012); National Cancer Institute (1990–2012); Hôpital Saint Eloi (2003); Arkansas Children's Nutrition Center (2025); The US Oncology Network (2009); PDL BioPharma (United States) (2006); BP (United States) (2001–2007); University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (2003); AbbVie Biotherapeutics (United States) (2009); University of Maryland, College Park (1990); Icahn School of Medicine at Mount Sinai (2016–2018)

Internal Med, College of Medicine

89 h-index 479 pubs 31,735 cited

Research Areas

Biomedical Subjects

Links

ORCID Google Scholar Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

John D. Shaughnessy's research focuses on the molecular mechanisms and classification of multiple myeloma, a cancer of plasma cells. His work has investigated the role of specific signaling pathways, such as Wnt and NF-κB, in the development of the disease, particularly in relation to osteolytic bone lesions. He has also contributed to the development and validation of gene expression-based models for classifying multiple myeloma, including identifying a high-risk subset defined by chromosomal abnormalities.

Shaughnessy is a highly cited researcher with a significant publication record and a substantial number of citations, reflecting his impact in the field. He leads a research group at the University of Arkansas for Medical Sciences and collaborates extensively with colleagues within the institution, including Fenghuang Zhan, Clyde Bailey, Guido Tricot, and Maurizio Zangari, with whom he has co-authored numerous publications. His research has also extended to studies in animal models, such as investigating calcium channel defects in tottering mutant mice related to absence epilepsy.

Metrics

h-index: 89
Publications: 479
Citations: 31,735

Positions

Professor 1996–present

University of Arkansas for Medical Sciences Internal Med, College of Medicine Institutional directory

Selected Publications

Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

Blood Cancer Journal DOI OpenAlex
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

DOI OpenAlex
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)

DOI OpenAlex
Gene Expression–Based prediction of 1q, 1p, 13q, and 17p chromosome ploidy in newly diagnosed and paired relapsed myeloma and across the plasma cell dyscrasia spectrum (2025)

DOI OpenAlex
The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes - insights from a single-site study (2025)

DOI OpenAlex
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging (2025)

DOI OpenAlex
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)

1 citation DOI OpenAlex
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)

3 citations DOI OpenAlex
Abstract 860: BCMA CAR-T cells releasing mutant CST6 N137D proteins further improve therapeutic effects in multiple myeloma (2025)

DOI OpenAlex
Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience (2025)

DOI OpenAlex
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)

1 citation DOI OpenAlex
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma (2025)

4 citations DOI OpenAlex
Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma (2025)

5 citations DOI OpenAlex
Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets (2025)

4 citations DOI OpenAlex
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)

5 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

As listed on this researcher's institutional profile.

Developmental Funds Pilot of the Southwest Oncology Group-SWOG-01047 NIH/Nat. Cancer Institute Principal Investigator
Gene expression profiling vs MRD assessment in Myeloma NIH Co-Investigator
Studying the role of APRIL and BAFF signaling in Myelomagenesis and its Therapy ZymoGenetics, Inc Principal Investigator
Preclinical Studies of the Mechanisms of Action of Velcade Millennium Pharmaceuticals, Inc. Principal Investigator
Molecular Diagnosis and Prognosis of Multiple Myeloma NIH/Nat. Cancer Institute Principal Investigator
U54 - Bioinformatics Core NIH/Nat. Cancer Institute via Baylor College of Medicine Principal Investigator
Myeloma-Microenvironment Interaction Dynamics NIH Co-Investigator
U54 - Administrative Core NIH/Nat. Cancer Institute via Baylor College of Medicine Principal Investigator